1. Home
  2. ALUR vs BIVI Comparison

ALUR vs BIVI Comparison

Compare ALUR & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALUR
    SELLHOLDBUYas of a day ago
  • BIVI
    SELLHOLDBUYas of a day ago
  • Stock Information
  • Founded
  • ALUR 2009
  • BIVI 2013
  • Country
  • ALUR United States
  • BIVI United States
  • Employees
  • ALUR N/A
  • BIVI N/A
  • Industry
  • ALUR
  • BIVI Biotechnology: Pharmaceutical Preparations
  • Sector
  • ALUR
  • BIVI Health Care
  • Exchange
  • ALUR Nasdaq
  • BIVI Nasdaq
  • Market Cap
  • ALUR 19.1M
  • BIVI 18.8M
  • IPO Year
  • ALUR N/A
  • BIVI N/A
  • Fundamental
  • Price
  • ALUR $2.54
  • BIVI $0.71
  • Analyst Decision
  • ALUR Strong Buy
  • BIVI Strong Buy
  • Analyst Count
  • ALUR 3
  • BIVI 1
  • Target Price
  • ALUR $22.83
  • BIVI $30.00
  • AVG Volume (30 Days)
  • ALUR 4.1M
  • BIVI 246.2K
  • Earning Date
  • ALUR 05-13-2025
  • BIVI 05-13-2025
  • Dividend Yield
  • ALUR N/A
  • BIVI N/A
  • EPS Growth
  • ALUR N/A
  • BIVI N/A
  • EPS
  • ALUR N/A
  • BIVI N/A
  • Revenue
  • ALUR $32,110,000.00
  • BIVI N/A
  • Revenue This Year
  • ALUR N/A
  • BIVI N/A
  • Revenue Next Year
  • ALUR $38.86
  • BIVI N/A
  • P/E Ratio
  • ALUR N/A
  • BIVI N/A
  • Revenue Growth
  • ALUR N/A
  • BIVI N/A
  • 52 Week Low
  • ALUR $2.15
  • BIVI $0.62
  • 52 Week High
  • ALUR $88.75
  • BIVI $7.50
  • Technical
  • Relative Strength Index (RSI)
  • ALUR 38.52
  • BIVI 29.23
  • Support Level
  • ALUR $2.72
  • BIVI $0.62
  • Resistance Level
  • ALUR $3.45
  • BIVI $1.00
  • Average True Range (ATR)
  • ALUR 0.43
  • BIVI 0.13
  • MACD
  • ALUR 0.04
  • BIVI -0.01
  • Stochastic Oscillator
  • ALUR 15.03
  • BIVI 14.04

Stock Price Comparison Chart: ALUR vs BIVI

ALUR
BIVI
JulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025April05101520253035ALUR VS BIVI

About ALUR Allurion Technologies Inc.

Allurion Technologies Inc is a medical device company that focuses on creating a best-in-class weight loss platform to treat overweight patients. Its platform, the Allurion Program, features the world's first and only swallowable, procedure-less intragastric balloon for weight loss and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion VCS. Its proprietary intragastric balloon, the Allurion Balloon, is in the form of a swallowed capsule that is administered to patients under the guidance of a healthcare provider without surgery, endoscopy, or anesthesia.

About BIVI BioVie Inc.

BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.

Share on Social Networks:

By browsing this website, you accept our Privacy Policy & Terms of Use